Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients

Annals of Intensive Care

Table 3 EUCAST MIC cut-off values defining susceptibility to new β-lactam/β-lactamase inhibitor combinations and cefiderocol for Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia

	Ceftolozane–tazobactam	Ceftazidime–avibactam	Imipenem–relebactam	Meropenem–vaborbactam	Cefiderocol
Enterobacterales	≤ 2 mg/L	≤ 8 mg/L	≤ 2 mg/L	≤ 8 mg/L	≤ 2 mg/L
Pseudomonas aeruginosa	≤ 4 mg/L	≤ 8 mg/L	≤ 2 mg/L	≤ 8 mg/L	≤ 2 mg/L
Acinetobacter baumannii	IR	NA	≤ 2 mg/L	≤ 2 mg/L ^a	NA
Stenotrophomonas maltophilia	IR	NA	IR	IR	NA

Source: www.eucast.org/clinical_breakpoints
EUCAST: European Committee on Antimicrobial Susceptibility Testing; MIC: minimal inhibitory concentration; IR: intrinsic resistance; NA: non-appropriate (species with intrinsically weak susceptibility to the considered drug or insufficient data to define a MIC cut-off value)
^aMIC cut-off for meropenem